Generated by AI
MediciNova Inc. is a biopharmaceutical company focused on developing novel small-molecule therapeutics for serious diseases with unmet medical needs. MediciNova’s current programs center on neurology, respiratory disease, and liver-related conditions, with development efforts concentrated on candidates such as MN-166 (ibudilast), MN-001 (tipelukast), and MN-221. Its pipeline targets a range of disorders including neurodegenerative, inflammatory, fibrotic, metabolic, and respiratory diseases, reflecting a portfolio built around differentiated mechanisms of action and clinical development across multiple indications. The company works through strategic alliances and clinical collaborations to advance its programs and support drug development from early research through later-stage trials. Headquartered in La Jolla, California, MediciNova Inc. occupies a specialized role in the biotechnology market by pursuing therapies for complex conditions where current treatment options remain limited.
Website4275 Executive Square
La Jolla, CA, 92037
United States
The latest articles about MNOV.
Summary of Sep 28's posts. Generated by AI.
Summary of Sep 17's posts. Generated by AI.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Summary of Sep 28's posts. Generated by AI.
Investors talking about MNOV also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.